There has been many exciting investments and advancements in the field, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs.

Hence, this August the 2nd RNA Assay Development & Screening Summit returns to Boston. Remaining as the first and only industry dedicated event on developing sensitive, robust and reproducible assay and screening methods, the 2024 agenda contains brand-new content and a refreshed pre-conference workshop day to enable accurate understanding and validation of RNA targets and RNA-small molecule binding to ensure therapeutic potential.

Join 80+ technical experts from the likes of AstraZeneca, Atavistik Bio, AbbVie, NextRNA Therapeutics, Expansion Therapeutics, Accent Therapeutics and more at the 2nd RNA Assay Development & Screening Summit 2024 to discuss assays and screening methods for understanding the true potential and mechanism of RNA-targeting small molecules to find treatments to currently ‘undruggable’ targets.

Event Link here.